Endovascular Development accepted to Uppsala Innovation Centre Business Accelerator

 
Two new companies have now been accepted to UICs accelerator program which supports innovative companies in Uppsala to scale up and increase their growth or grow internationally.  

The program offers companies a unique access to tailored business support and an investment of SEK 500,000. The companies accepted are Endovascular Development and Stardots.

The UIC Business Accelerator business development program accepts innovative companies that are ready to scale up their business further or find a new market. During the program, the companies gain access to specialised knowledge based on the company's unique needs in areas such as law, finance, marketing, leadership or technology. The life science company Endovascular Development and the E-health company Stardots have now been accepted.

Endovascular Development has developed a new Guidewire Fixator which enables safer surgery and reduces operating time along with improving treatments in endovascular surgery.

Stardots, AI-TRUST™ will utilize the cloud and AI to deliver software-as-a-drug for those suffering from Parkinson’s Disease. The digital health platform will significantly improve PD patients’ quality of life, substantially reduce treatment cost and offer an aid to clinical trials for MedTech and pharmaceutical companies.

"These two companies are examples of how UIC attracts innovation that can really make a difference for society as a whole and people as individuals. It will be very interesting to support the companies, partly through the accelerator but also through the investment offered by Linnéa Capital, says Patric Karlsson, Program Manager at UIC.
UIC Business Accelerator runs for two to three years and is for innovative growth companies. The companies are offered tailor-made business development support by hand-picked business coaches from the business community, with specialised skills based on the company's unique needs.

Companies accepted to the accelerator program are also offered an investment of SEK 500,000 from Linnéa Capital. The aim is to strengthen the companies' financial situation and increase growth opportunities. 
 
For more information:
Patric Karlsson, Program Manager and Program Manager UIC Business Accelerator
 UICTel:  +46 705 45 36 75E-mail:  patric.karlsson@uic.se
Vedrana Ilic, kommunikatörUICTel: 0708-51 97 04E-post: 
vedrana.ilic@uic.se
About UIC
UIC (Uppsala Innovation Centre) is one of the country's foremost business incubators and accelerators and is ranked by UBI Global among the world's top 5 best public business incubators. UIC offers tailored business development support, knowledge and networking to innovative startups and growth companies that want to develop their business, scale up or reach an international market. UIC does not take any ownership stakes and is industry independent. UIC works closely with the business community through, for example, a large network of business coaches from the business world and some twenty UIC partners, all of whom contribute to the development of uic companies together with UIC. UIC operates in Uppsala County and Södertälje Municipality. The owners of UIC are equally STUNS, Uppsala Municipality, SLU Holding and Uppsala University Holding. UIC is part of Vinnova's Incubation Support – Excellence program.  www.uic.se

Re-classification of LGF now complete and looking to the future

Endovab is very happy to announce that the medical device re-classification process now is completed: The Liungman Guidewire Fixator CE mark Class 3 (MDD) is valid until May 2024.

We look forward to continuing to supply this key tool to all endovascular centres in Europe, which will help them make interventions in the aorta and the peripheral artery safer and in a shorter time.

2017

Dr David Deaton is the former Chief of Vascular and Endovascular surgery at Georgetown University Hospital and was most recently a staff vascular surgeon at the Cleveland Clinic.   Currently he is the chief medical officer at Syntactx, a clinical research organization, in New York in addition to a variety of consulting positions for start-up and established medical device firms. Dr Deaton has a long experience of vascular surgery and has been primarily involved in the development of several well-known medical devices, to include the first approved aortic endograft in the US (Ancure / Guidant) and, more recently, the Aptus EndoAnchor.  
 
Dr Deaton’s passion for innovation originates from the early 90’s when he became one of the few vascular surgeons involved in the pre-clinical development of the first bifurcated endograft introduced into clinical trials and he is a strong believer in interaction between surgeons and technical development. In this interview from the Veith Symposium in 2016, he explains his view on collaboration and development to improve treatment and patient outcome.

“I think that Endovab has very interesting technology that enables a variety of new treatment methods and opportunities for the aortic segment but also for other peripheral interventional techniques”, says Dr David Deaton.
 
David joins Endovab in the capacity of strategic clinical advisor and member of the board. “We are very happy to have Dr Deaton onboard with us, his experience, network, and insights to the American market are very valuable for us. This is particularly relevant now, as we are looking to expand the guidewire fixator technology to peripheral intervention, where the US is the dominating market.” Says Linus Bosaeus, CEO Endovab.

Läs hela inlägget »

Dr Liungman is presenting the first results from the LGF registry study for complex aortic repair at the Veith Symposium 2017. This includes experiences with the LGF from Chimney and Snorkel repair, as well as recent cases of arch aneurysm repair using pre-lined fenestrated grafts. 
 
See you in New York!
Saturday, November 18, 2017 at 11am in the Grand Ballroom East, 3rd Floor

Läs hela inlägget »

A technical paper describing a new method for f-EVAR has just been published in INNOVATION. The new method entails fixated guidewires and retrograde lining of the aortic branches, which eliminates the unpredictable searching of the branched vessels during fenestrated endovascular aortic repair. 
"This publication is an important step in spreading the knowledge and awareness of a new method to solve a well know challenge in fenestrated and branched aortic repair.” says Krister Liungman, Inventor of the Guidewire Fixator. 

Läs hela inlägget »

Endovab obtains further granted patent in Canada. The patent relate to a guidewire fixator, a new medical device that enables distal guidewire stability. Many endovascular procedures can benefit from a stable guidewire position, such as peripheral angioplasty as well as f-EVAR and Ch-EVAR.

 “This patent has been approved in several countries worldwide during the last year, and further acceptance is expected. This relates to one of our core technologies and we are pleased to see that the IP is growing as planned” comments Linus Bosaeus, CEO Endovab.

Läs hela inlägget »


The Endovab platform for distal guidewire fixation enables a new and patented drug delivery opportunity. By distal fixation of a micro catheter, a drug could be delivered from an external pump directly to a target site while the patient is active, without catheter displacement.
 
Intra-arterial drug delivery is known to allow for higher local drug concentration while reducing side effects compared to systemic delivery. Targeted drug delivery also allows the use of the primary non-metabolized synthesis, prior to first passage metabolism in the liver or systemically.
 
Do you have a drug that needs targeted delivery?
 
For further information about our drug delivery concept and IP, please contact us at info.endovab.com. 

Läs hela inlägget »

Endovab has recently had another patent relating to the Liungman Guidewire Fixator (LGF) technology accepted in France, Germany, Great Britain and Italy. The patent relates the mechanism that allows ‘over the wire’ delivery and retrieval.
 
“The ability to delivery and particularly retrieve an over-the-wire device requires a flexible and reliable delivery system. Our solutions is uniquely simplistic and easy to use, while at the same time providing accurate and reliably functionality.” Comments Krister Liungman, Founder of Endovab and inventor of the LGF.

Läs hela inlägget »

When using pre-lined branched guidewires, there is always a risk for wire entanglement. We propose using multi lumen catheters to obtain parallel wires and this video demonstrates the method we propose to sort out and prevent entanglement when using three guidewires, for example for a pre-lined pararenal case as shown.
 
We believe using a three-lumen catheter works great and offers a very rapid and intuitive sorting step.
 
Are you familiar with any existing multi lumen catheter or sheath that can hold three 0,035” guidewires and be suitable for this manoeuvre? info@endovab.com

Läs hela inlägget »

The LGF is now being part of a chimney registry study managed by Jean-Paul De Vries at St. Antonius Hospital Nieuwegein in the Netherlands. As part of a larger registry for chimney procedures, the LGF is used to facilitate a stable guidewire position for the chimney grafts throughout the procedure. A stable position supports delivery and positioning of the chimney graft or grafts, as well as securing the position while deploying and expanding multiple grafts simultaneously.



“The LGF is quite an interesting tool that has the potential to improve and simplify chimney procedures, and to reduce guidewire manipulations in the visceral arteries. We are happy to be the first team to work on this indication together with Endovab” says Jean-Paul de Vries, Head of Vascular Sugery at St. Antonius Hospital Nieuwegein.

Läs hela inlägget »

Endovab has been granted a new European patent that will be issued on the 5th of April. The patent relates to technology for delivering and retrieving a medical device inside the body. The flexible mechanism has been designed to allow delivery and retrieval in tortuous anatomies and is currently utilised in the Liungman Guidewire Fixator. 

You will find more information on Endovab IP here

Läs hela inlägget »

Unstable guidewire position during chimneys and snorkel procedures is an imminent risk that requires experience and attention. Professor Mario Lachat at the University of Zürich is one of the international pioneers of parallel graft and sandwich techniques using chimneys and snorkels to both visceral and arch branches.
 
As a scientific board member, Mario Lachat was the first to use the LGF in a snorkel case in March 2017 as a pilot for a planned study. The LGF was used to secure the guidewire position in the right renal artery while deploying three Viabahn stentgraft that were then reinforced with bare Wallstents. The entire procedure entailed a full metal jacket stentgraft treatment, including parallel grafts with snorkels connecting the renal arteries and a chimney for the superior mesenteric artery. 
 
The procedure was successfully completed and the LGF performed as intended.
 
“I liked the device, it’s a great tool” – Mario Lachat.
 
If you are interested to learn more about the chimney and snorkel technique using the LGF, or if you want to sign up interest for early adoption and study participation, please contact Dr Krister Liungman, Krister.liungman@endovab.com.

Läs hela inlägget »

The facilitated method for f-EVAR using the LGF has been developed to make the procedure stepwise and predictable. By catheterisation of the branch vessels prior to insertion of the main stentgraft, the connection of the target vessels and the fenestrated graft is made on the table prior to introducing the stentgraft. This video describes the steps in the procedure illustrated in a pig model.

Läs hela inlägget »

Our clinical lead Dr Krister Liungman presented the Liungman Guidewire Fixator at LINC this Thursday. It was a busy week for all participants and the LINC event attracted a seamless mix of clinicians and industry, over 5000 participants! Radiation awareness was a hot topic and it seems like the industry is also aiming to reduce procedure duration by offering pre-loaded catheters and through-and-through wires. If you like to know more about what Dr Liungman presented, don’t hesitate to contact us at info@endovab.com

Läs hela inlägget »

Results from the LGF clinical study and more will be presented at the LINC conference, in the Innovation Forum, Thursday 26th at 12:54 in room 7. If you want to know more, please email us at info@endovab.com and we will send you a copy of the clinical report internal paper. 

Läs hela inlägget »

2017

Dr David Deaton is the former Chief of Vascular and Endovascular surgery at Georgetown University Hospital and was most recently a staff vascular surgeon at the Cleveland Clinic.   Currently he is the chief medical officer at Syntactx, a clinical research organization, in New York in addition to a variety of consulting positions for start-up and established medical device firms. Dr Deaton has a long experience of vascular surgery and has been primarily involved in the development of several well-known medical devices, to include the first approved aortic endograft in the US (Ancure / Guidant) and, more recently, the Aptus EndoAnchor.  
 
Dr Deaton’s passion for innovation originates from the early 90’s when he became one of the few vascular surgeons involved in the pre-clinical development of the first bifurcated endograft introduced into clinical trials and he is a strong believer in interaction between surgeons and technical development. In this interview from the Veith Symposium in 2016, he explains his view on collaboration and development to improve treatment and patient outcome.

“I think that Endovab has very interesting technology that enables a variety of new treatment methods and opportunities for the aortic segment but also for other peripheral interventional techniques”, says Dr David Deaton.
 
David joins Endovab in the capacity of strategic clinical advisor and member of the board. “We are very happy to have Dr Deaton onboard with us, his experience, network, and insights to the American market are very valuable for us. This is particularly relevant now, as we are looking to expand the guidewire fixator technology to peripheral intervention, where the US is the dominating market.” Says Linus Bosaeus, CEO Endovab.

Read the full post »

Dr Liungman is presenting the first results from the LGF registry study for complex aortic repair at the Veith Symposium 2017. This includes experiences with the LGF from Chimney and Snorkel repair, as well as recent cases of arch aneurysm repair using pre-lined fenestrated grafts. 
 
See you in New York!
Saturday, November 18, 2017 at 11am in the Grand Ballroom East, 3rd Floor

Read the full post »

A technical paper describing a new method for f-EVAR has just been published in INNOVATION. The new method entails fixated guidewires and retrograde lining of the aortic branches, which eliminates the unpredictable searching of the branched vessels during fenestrated endovascular aortic repair. 
"This publication is an important step in spreading the knowledge and awareness of a new method to solve a well know challenge in fenestrated and branched aortic repair.” says Krister Liungman, Inventor of the Guidewire Fixator. 

Read the full post »

Endovab obtains further granted patent in Canada. The patent relate to a guidewire fixator, a new medical device that enables distal guidewire stability. Many endovascular procedures can benefit from a stable guidewire position, such as peripheral angioplasty as well as f-EVAR and Ch-EVAR.

 “This patent has been approved in several countries worldwide during the last year, and further acceptance is expected. This relates to one of our core technologies and we are pleased to see that the IP is growing as planned” comments Linus Bosaeus, CEO Endovab.

Read the full post »


The Endovab platform for distal guidewire fixation enables a new and patented drug delivery opportunity. By distal fixation of a micro catheter, a drug could be delivered from an external pump directly to a target site while the patient is active, without catheter displacement.
 
Intra-arterial drug delivery is known to allow for higher local drug concentration while reducing side effects compared to systemic delivery. Targeted drug delivery also allows the use of the primary non-metabolized synthesis, prior to first passage metabolism in the liver or systemically.
 
Do you have a drug that needs targeted delivery?
 
For further information about our drug delivery concept and IP, please contact us at info.endovab.com. 

Read the full post »

Endovab has recently had another patent relating to the Liungman Guidewire Fixator (LGF) technology accepted in France, Germany, Great Britain and Italy. The patent relates the mechanism that allows ‘over the wire’ delivery and retrieval.
 
“The ability to delivery and particularly retrieve an over-the-wire device requires a flexible and reliable delivery system. Our solutions is uniquely simplistic and easy to use, while at the same time providing accurate and reliably functionality.” Comments Krister Liungman, Founder of Endovab and inventor of the LGF.

Read the full post »

When using pre-lined branched guidewires, there is always a risk for wire entanglement. We propose using multi lumen catheters to obtain parallel wires and this video demonstrates the method we propose to sort out and prevent entanglement when using three guidewires, for example for a pre-lined pararenal case as shown.
 
We believe using a three-lumen catheter works great and offers a very rapid and intuitive sorting step.
 
Are you familiar with any existing multi lumen catheter or sheath that can hold three 0,035” guidewires and be suitable for this manoeuvre? info@endovab.com

Read the full post »

The LGF is now being part of a chimney registry study managed by Jean-Paul De Vries at St. Antonius Hospital Nieuwegein in the Netherlands. As part of a larger registry for chimney procedures, the LGF is used to facilitate a stable guidewire position for the chimney grafts throughout the procedure. A stable position supports delivery and positioning of the chimney graft or grafts, as well as securing the position while deploying and expanding multiple grafts simultaneously.



“The LGF is quite an interesting tool that has the potential to improve and simplify chimney procedures, and to reduce guidewire manipulations in the visceral arteries. We are happy to be the first team to work on this indication together with Endovab” says Jean-Paul de Vries, Head of Vascular Sugery at St. Antonius Hospital Nieuwegein.

Read the full post »

Endovab has been granted a new European patent that will be issued on the 5th of April. The patent relates to technology for delivering and retrieving a medical device inside the body. The flexible mechanism has been designed to allow delivery and retrieval in tortuous anatomies and is currently utilised in the Liungman Guidewire Fixator. 

You will find more information on Endovab IP here

Read the full post »

Unstable guidewire position during chimneys and snorkel procedures is an imminent risk that requires experience and attention. Professor Mario Lachat at the University of Zürich is one of the international pioneers of parallel graft and sandwich techniques using chimneys and snorkels to both visceral and arch branches.
 
As a scientific board member, Mario Lachat was the first to use the LGF in a snorkel case in March 2017 as a pilot for a planned study. The LGF was used to secure the guidewire position in the right renal artery while deploying three Viabahn stentgraft that were then reinforced with bare Wallstents. The entire procedure entailed a full metal jacket stentgraft treatment, including parallel grafts with snorkels connecting the renal arteries and a chimney for the superior mesenteric artery. 
 
The procedure was successfully completed and the LGF performed as intended.
 
“I liked the device, it’s a great tool” – Mario Lachat.
 
If you are interested to learn more about the chimney and snorkel technique using the LGF, or if you want to sign up interest for early adoption and study participation, please contact Dr Krister Liungman, Krister.liungman@endovab.com.

Read the full post »

The facilitated method for f-EVAR using the LGF has been developed to make the procedure stepwise and predictable. By catheterisation of the branch vessels prior to insertion of the main stentgraft, the connection of the target vessels and the fenestrated graft is made on the table prior to introducing the stentgraft. This video describes the steps in the procedure illustrated in a pig model.

Read the full post »

Our clinical lead Dr Krister Liungman presented the Liungman Guidewire Fixator at LINC this Thursday. It was a busy week for all participants and the LINC event attracted a seamless mix of clinicians and industry, over 5000 participants! Radiation awareness was a hot topic and it seems like the industry is also aiming to reduce procedure duration by offering pre-loaded catheters and through-and-through wires. If you like to know more about what Dr Liungman presented, don’t hesitate to contact us at info@endovab.com

Read the full post »

Results from the LGF clinical study and more will be presented at the LINC conference, in the Innovation Forum, Thursday 26th at 12:54 in room 7. If you want to know more, please email us at info@endovab.com and we will send you a copy of the clinical report internal paper. 

Read the full post »

ARCHIVE

LATEST NEWS

Copyright © 2019. Endovascular Development AB. All Rights Reserved.